TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04049669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Radiation
Description: Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full-dose Radiation
Description: Palliative full-dose radiation plan to all known sites of disease (\>50 Gy to brain, \>45 Gy to spine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
Study: NCT01744782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103
Description: Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
Study: NCT02273050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: Tablet, Oral, 5 mg, Once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5 mg
Description: Tablet, Oral, 5 mg, Once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 5 mg for Saxagliptin
Description: Tablet, Oral, 5 mg, Once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 500 mg for metformin (with titration)
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 500 mg with titration
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg with titration
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Study: NCT00689845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: Given IV
Study: NCT04003818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEICOPLANIN
Description: Pharmaceutical form:solution for oral administration Route of administration: oral
Study: NCT02785653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
Study: NCT02409329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helpline and A1c results
Description: Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
Study: NCT01126801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Oral estradiol 1.0 mg/day for four weeks.
Study: NCT02409329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpline and A1c results
Description: Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpline and A1c results
Description: Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH + FAMS
Description: The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
Study: NCT01588535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
Study: NCT03513614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored axillary surgery - both Arms
Description: Axillary lymph node dissection - Arm A
Study: NCT01588535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo solution, five drops in affected ear canal each hour as needed
Study: NCT03513614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored axillary surgery - both Arms
Description: Axillary lymph node dissection - Arm A

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy - Arm A
Description: Regional nodal irradiation excluding the dissected axilla - Arm A

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy - Arm B
Description: Regional nodal irradiation including the full axilla - Arm B
Study: NCT04678258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HR electroanatomic mapping and MVG catheter ablation
Description: High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bipolar mapping and linear catheter ablation
Description: Bipolar mapping and conventional anatomic linear catheter ablation
Study: NCT01126801

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control matched to estradiol tablets. Daily dosing for one month.
Study: NCT03076320

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDF+M-DDO
Description: Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A+PBO
Description: Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
Study: NCT03442569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
Study: NCT01117467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation scenario
Description: Students performing their scenario will be paired, not solo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation scenario
Description: Students will perform their simulation scenario solo and receive feedback within the group
Study: NCT02808819

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 8 weeks
Study: NCT03041207

Intervention type: BEHAVIORAL
Intervention: Development and implementation of an antibiotic guideline
Description: A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection

Intervention type: BEHAVIORAL
Intervention: Development and implementation of an antibiotic guideline
Description: A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
Study: NCT01118117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Misago™ Self-Expanding Stent System
Description: Transcatheter placement of an intravascular stent(s)
Study: NCT03588650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX20
Description: a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
Study: NCT02118168

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is foreseen in this Observational Study
Study: NCT02839798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST (NeoSync EEG Synchronized TMS)
Description: The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
Study: NCT02642237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluenz
Description: intranasal inoculation with Fluenz

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fluenz
Description: intranasal inoculation with Fluenz

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Study: NCT01416116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: oral
Study: NCT01955512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00136760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contingent reinforcement plus placebo
Description: contingent reinforcement plus placebo (3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-contingent reinforcement plus bupropion
Description: non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-contingent reinforcement plus placebo
Description: Non-contingent reinforcement plus placebo
Study: NCT02388698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical swab
Description: Cervical Swab at baseline.~HPV testing at recurrence, if applicable.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-CT
Description: PET-CT will be completed 3 month post chemoradiation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma HPV
Description: Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
Study: NCT02773069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Church Bridge Project
Description: Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
Study: NCT02731508

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bihemispheric transcranial direct current stimulation
Description: 5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihemispheric transcranial direct current stimulation
Description: 5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
Study: NCT04095988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic microbiota reconstitution
Description: gastroscopic microbiota Infusion (Verum)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Allogeneic microbiota reconstitution
Description: gastroscopic saline Infusion (placebo)
Study: NCT03011840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information leaflet
Description: Patient information leaflet with instructions to be carried out before procedure under general anesthesia
Study: NCT04210596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation at the buccal aspect of single implants
Description: Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation at the buccal aspect of single implants
Description: Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
Study: NCT04467606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a discharge planning using the strategy of motivational interviewing
Description: The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
Study: NCT02122172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib dimaleate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03165513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhGAP-IG
Description: psychosocial interventions
Study: NCT04461405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTEGRATE-D
Description: INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
Study: NCT03241758

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound
Description: Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
Study: NCT00390000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Correlative study
Study: NCT03063775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioOss® + Mucograft Seal®
Description: Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FGG + Bio-Oss®
Description: Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FGG + Gelatine sponge (Spongostan®)
Description: Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
Study: NCT00233987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg IV 2 days before transplant.
Study: NCT03063775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spongostan®+ Mucograft® Seal
Description: Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
Study: NCT00850343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Subcutaneous (SC) injection
Study: NCT00233987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg IV over 4 hours 4 days before transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 150 mg/m\^2 IV 1 day before transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: 2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
Study: NCT02704195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral reduction of stimulation
Description: 30% unilateral reduction of Subthalamic nucleus stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Subthalamic nucleus stimulation
Description: This arm is the reference, with the best stimulation parameters